Business
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families
About this update from Neurogene Inc.
NEW YORK --(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum . Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events , where a replay of the event will also be available for a limited time. About Neurogene Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401 , as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn . View source version on businesswire.com : https://www.businesswire.com/news/home/20260311342818/en/ Company Contact: Mike Devine Executive Director, Corporate Communications [email protected] Investor Contact: Argot Partners [email protected] Source: Neurogene Inc.